Literature DB >> 22019270

The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers.

Xanthia F Samaropoulos1, Laney Light, Walter T Ambrosius, Santica M Marcovina, Jeffrey Probstfield, David C Goff.   

Abstract

AIMS: To determine whether intensive risk factor management reduced markers of inflammation in middle-aged and older people with type 2 diabetes who either had, or were at risk for cardiovascular disease (CVD), and whether these effects were mediated by adiposity.
METHODS: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was a multicenter double 2 by 2 factorial randomized controlled trial of 10,251 middle-aged and older people who had type 2 diabetes, a GHbA1c of 7.5% or greater, and evidence of CVD or CVD risk factors. Biomarkers were assessed in a subset of 562 participants. Intervention effects on high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) were tested using linear regression models.
RESULTS: A significantly lower average hs-CRP was noted in the intensive versus the standard glycemic group (p=0.029). Adjusting for change in BMI or waist circumference resulted in larger differences in adjusted hs-CRP (p<0.001 and p<0.002, respectively) between the glycemic intervention groups.
CONCLUSIONS: Intensive glycemic control was associated with a reduction in hs-CRP in this study population. Intervention associated increases in adiposity suppressed the beneficial effect of intensive glycemic control on lowering hs-CRP.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22019270     DOI: 10.1016/j.diabres.2011.09.027

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  8 in total

Review 1.  Glucose targets for preventing diabetic kidney disease and its progression.

Authors:  Marinella Ruospo; Valeria M Saglimbene; Suetonia C Palmer; Salvatore De Cosmo; Antonio Pacilli; Olga Lamacchia; Mauro Cignarelli; Paola Fioretto; Mariacristina Vecchio; Jonathan C Craig; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2017-06-08

2.  Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD.

Authors:  Hetal S Shah; Mario Luca Morieri; Santica M Marcovina; Ronald J Sigal; Hertzel C Gerstein; Michael J Wagner; Alison A Motsinger-Reif; John B Buse; Peter Kraft; Josyf C Mychaleckyj; Alessandro Doria
Journal:  Diabetes Care       Date:  2017-11-28       Impact factor: 19.112

3.  Prognostic Importance of C-Reactive Protein in High Cardiovascular Risk Patients With Type 2 Diabetes Mellitus: The Rio de Janeiro Type 2 Diabetes Cohort Study.

Authors:  Claudia R L Cardoso; Nathalie C Leite; Gil F Salles
Journal:  J Am Heart Assoc       Date:  2016-10-26       Impact factor: 5.501

Review 4.  Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes.

Authors:  Ferdinando Carlo Sasso; Luca Rinaldi; Nadia Lascar; Aldo Marrone; Pia Clara Pafundi; Luigi Elio Adinolfi; Raffaele Marfella
Journal:  J Diabetes Res       Date:  2018-10-04       Impact factor: 4.011

Review 5.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24

6.  Proinflammatory and prothrombotic state in subjects with different glucose tolerance status before cardiovascular disease.

Authors:  Irma Isordia-Salas; María Eugenia Galván-Plata; Alfredo Leaños-Miranda; Eberth Aguilar-Sosa; Francisco Anaya-Gómez; Abraham Majluf-Cruz; David Santiago-Germán
Journal:  J Diabetes Res       Date:  2014-03-17       Impact factor: 4.011

7.  Racial and ethnic disparities in predictors of glycemia: a moderated mediation analysis of inflammation-related predictors of diabetes in the NHANES 2007-2010.

Authors:  Sarah Nowlin; Charles M Cleland; Niyati Parekh; Holly Hagan; Gail Melkus
Journal:  Nutr Diabetes       Date:  2018-10-22       Impact factor: 5.097

8.  PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid.

Authors:  Mario Luca Morieri; Hetal S Shah; Jennifer Sjaarda; Petra A Lenzini; Hannah Campbell; Alison A Motsinger-Reif; He Gao; Laura Lovato; Sabrina Prudente; Assunta Pandolfi; Marcus G Pezzolesi; Ronald J Sigal; Guillaume Paré; Santica M Marcovina; Daniel M Rotroff; Elisabetta Patorno; Luana Mercuri; Vincenzo Trischitta; Emily Y Chew; Peter Kraft; John B Buse; Michael J Wagner; Sharon Cresci; Hertzel C Gerstein; Henry N Ginsberg; Josyf C Mychaleckyj; Alessandro Doria
Journal:  Diabetes       Date:  2020-01-23       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.